Previous 10 | Next 10 |
Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions Dr. Michael Egholm, Former CTO of Danaher Life Sciences, to Assume Role of CEO and Join Board of Directors Following Close; ...
Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth quarter and 12% for full year as new Biomark OEM and CyTOF XT ins...
The 7-day moving average for daily COVID-19 cases reached 240,408, a level not seen since January when the country was in the throes of the Delta variant. CDC data shows that the 7-day moving average peaked on Jan. 11 with 250,437 cases. Given recent trends, it is likely that figure will be s...
The FDA says that early data indicates that antigen tests for COVID are able to detect the Omicron variant, but may have reduced sensitivity. Sensitivity is the term used to describe the accuracy of a test in the form of the true positive rate. If a test has lower sensitivity, it means that f...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Changing the rules The Centers for Disease Control and Prevention is updating recommendations for COVID-19 control, shortening isolation restrictions from ...
In a meeting with some of the nation's governors, President Biden pledged to support states struggling with the Omicron variant, but acknowledged that they will need to take the lead in controlling the pandemic. Arkansas Governor Asa Hutchinson, who is chair of the National Governors Associat...
Fourth vaccine: Israel is set to become the first country in the world to administer a fourth COVID-19 vaccine, which would give "greater protection in the face of Omicron." The first eligible group to receive the vaccine will be people age 60 and older, as well as the immunocompromised and m...
Fluidigm (NASDAQ:FLDM) has confirmed that Omicron variant B.1.1.529 does not impact the capability of the Fluidigm Advanta Dx SARS-CoV-2 RT-PCR Assay to detect COVID-19, based on in silico analyses of the most current databases. Shares up 2.6% premarket at $4.36. To date, none ...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today confirmed that Omicron variant B.1.1.529, designated by the World Health Or...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jo...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...